Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy

Jing, Hui; Cheng, Wen; Li, Shouqiang; Wu, Bolin; Leng, Xiaoping; Xu, Shouping; Tian, Jiawei

doi:10.1016/j.colsurfb.2016.06.037

Cited by 60 publications

(32 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDM2 [ 77 ], cyclin-dependent kinase (CDK) 11 and casein kinase 2 (CK2) [ 78 ], c-Myc [ 79 ], survivin (also known as BIRC-5, an inhibitor of apoptosis protein) [ 80 , 81 ], mTORC 2 [ 82 ], Ataxia-telangiectasia mutated (ATM) protein [ 83 ], monopolar spindle 1 (MPS1, most commonly known TTK protein kinase) and cell division cycle protein 20 (CDC20) [ 84 ], Heparin-binding EGF-like growth factor (HB-EGF) [ 85 ], epidermal growth factor receptors (EGFR) [ 86 , 87 , 88 ], CXCR-4 [ 89 ], luciferase mRNA protein [ 90 ], and enhanced green fluorescent protein (eGFP) [ 91 ] are overexpressed in TNBC cells. Gene function studies showed that silencing any of these molecular factors using siRNA-mediated nanoparticles caused significant tumor growth suppression.…”

Section: Pre-clinical Activity Of Engineered Sirna-mediated Therapmentioning

confidence: 99%

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Hattab

Bakhtiar

2020

Pharmaceutics

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNBC patients, making traditional chemotherapeutic agents the only current appropriate regimen. Patients’ predisposition to relapse and metastasis, chemotherapeutics’ cytotoxicity and resistance and poor prognosis of TNBC necessitates researchers to investigate different novel-targeted therapeutics. The role of small interfering RNA (siRNA) in silencing the genes/proteins that are aberrantly overexpressed in carcinoma cells showed great potential as part of TNBC therapeutic regimen. However, targeting specificity, siRNA stability, and delivery efficiency cause challenges in the progression of this application clinically. Nanotechnology was highlighted as a promising approach for encapsulating and transporting siRNA with high efficiency-low toxicity profile. Advances in preclinical and clinical studies utilizing engineered siRNA-loaded nanotherapeutics for treatment of TNBC were discussed. Specific and selective targeting of diverse signaling molecules/pathways at the level of tumor proliferation and cell cycle, tumor invasion and metastasis, angiogenesis and tumor microenvironment, and chemotherapeutics’ resistance demonstrated greater activity via integration of siRNA-complexed nanoparticles.

show abstract

Section: Pre-clinical Activity Of Engineered Sirna-mediated Therapmentioning

confidence: 99%

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Hattab

Bakhtiar

2020

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…When NBs reached the target site, they were disintegrated under external ultrasonic irradiation, releasing CPPs and siEGFR to achieve cytoplasmic delivery. Since CPPs had a strong nonspecific binding effect with all the cells, it is beneficial to attach a targeting ligand onto the NBs to induce cell specific binding and receptor-mediated endocytosis [ 67 ]. Therefore, CPPs-siRNA in NBs has been modified with a targeting ligand and triggered to be delivered by ultrasound [ 68 ].…”

Section: Common Chemical Modification Strategies For On Drugsmentioning

confidence: 99%

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation

Sun

Zhao

et al. 2017

Molecules

View full text Add to dashboard Cite

Oligonucleotide (ON) drugs, including small interfering RNA (siRNA), microRNA (miRNA) and antisense oligonucleotides, are promising therapeutic agents. However, their low membrane permeability and sensitivity to nucleases present challenges to in vivo delivery. Chemical modifications of the ON offer a potential solution to improve the stability and efficacy of ON drugs. Combined with nanoparticle encapsulation, delivery at the site of action and gene silencing activity of chemically modified ON drugs can be further enhanced. In the present review, several types of ON drugs, selection of chemical modification, and nanoparticle-based delivery systems to deliver these ON drugs are discussed.

show abstract

“…Other complex MBs have been produced by combining cationic polymer (PEI, polyallanine, poly- l -lysine), cationic peptides as cell penetrating peptide or lipoplexes comprising cationic liposomes with nucleic acids ( Table 1 ). The latter required the use of micelles or avidin/biotin linkage [ 75 ]. Despite being interesting, one of the drawbacks of these formulations is their size and the softness that could limit the diffusion.…”

Section: Cationic Mbs For Gene Deliverymentioning

confidence: 99%

Cationic gas-filled microbubbles for ultrasound-based nucleic acids delivery

et al. 2017

View full text Add to dashboard Cite

The use of ultrasound has gained great interest for nucleic acids delivery. Ultrasound can reach deep tissues in non-invasive manner. The process of sonoporation is based on the use of low-frequency ultrasound combined with gas-filled microbubbles (MBs) allowing an improved delivery of molecules including nucleic acids in the insonified tissue. For in vivo gene transfer, the engineering of cationic MBs is essential for creating strong electrostatic interactions between MBs and nucleic acids leading to their protection against nucleases degradation and high concentration within the target tissue. Cationic MBs must be stable enough to withstand nucleic acids interaction, have a good size distribution for in vivo administration, and enough acoustic activity to be detected by echography. This review aims to summarize the basic principles of ultrasound-based delivery and new knowledge acquired in these recent years about this method. A focus is made on gene delivery by discussing reported studies made with cationic MBs including ours. They have the ability for efficient delivery of plasmid DNA (pDNA), mRNA or siRNA. Last, we discuss about the key challenges that have to be faced for a fine use of this delivery system.

show abstract

Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy

Cited by 60 publications

References 34 publications

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation

Cationic gas-filled microbubbles for ultrasound-based nucleic acids delivery

Contact Info

Product

Resources

About